Boston Therapeutics, Inc. (25)
Browse by Contract Category
Contracts
-
Offer Letter, dated February 28, 2022
(Filed With SEC on May 10, 2022)
-
First Amendment to Development and License Agreement, dated September 1, 2018 by and between RedPharm (Beijing) Biotechnology Co., Ltd. and Medical Technology Associates II, Inc....
(Filed With SEC on April 12, 2022)
-
Consent, Amendment and Waiver, dated March 22, 2022
(Filed With SEC on March 24, 2022)
-
Agreement and Plan of Merger, dated February 2, 2021, by and between Boston Therapeutics, Inc.., BTHE Acquisition Inc. and Nanomix, Inc
(Filed With SEC on February 2, 2021)
-
Form of Debt Settlement and Release Agreement
(Filed With SEC on February 2, 2021)
-
Development and License Agreement, dated September 26, 2017 by and between RedPharm (Beijing) Biotechnology Co., Ltd. and Medical Technology Associates II, Inc. and Nanomix, Inc
(Filed With SEC on April 12, 2022)
-
Description of Securities of Nanomix Corporation
(Filed With SEC on April 12, 2022)
-
Securities Purchase Agreement, dated March 23, 2022
(Filed With SEC on March 24, 2022)
-
Form of Warrant, dated March 23, 2022
(Filed With SEC on March 24, 2022)
-
Consent, Amendment and Waiver, dated February 24, 2022
(Filed With SEC on March 1, 2022)
-
Securities Purchase Agreement, dated February 28, 2022
(Filed With SEC on March 1, 2022)
-
Form of Warrant, dated February 28, 2022
(Filed With SEC on March 1, 2022)
-
Form of Senior Secured Convertible Note, dated February 28, 2022
(Filed With SEC on March 1, 2022)
-
Form of Exchange Agreement, dated June 25, 2021, with existing holders of convertible promissory notes
(Filed With SEC on June 29, 2021)
-
Guaranty, dated June 25, 2021, by each of the Companys subsidiaries in favor of HT Investments MA LLC, in its capacity as collateral agent
(Filed With SEC on June 29, 2021)
-
Security and Pledge Agreement, dated June 25, 2021, by and between Boston Therapeutics, Inc, each of the Companys subsidiaries and HT Investments MA LLC, in its capacity as...
(Filed With SEC on June 29, 2021)
-
Registration Rights Agreement, dated June 25, 2021, by and between Boston Therapeutics, Inc. and the buyers signatory thereto
(Filed With SEC on June 29, 2021)
-
Securities Purchase Agreement, dated June 25, 2021, by and between Boston Therapeutics, Inc. and the buyers signatory thereto
(Filed With SEC on June 29, 2021)
-
Form of Warrant, dated June 25, 2021
(Filed With SEC on June 29, 2021)
-
Form of Senior Secured Convertible Note, dated June 25, 2021
(Filed With SEC on June 29, 2021)
-
Form of 10% Promissory Note issued by Nanomix, Inc. to Boston Therapeutics Inc
(Filed With SEC on May 12, 2021)
-
Form of Promissory Note dated April 30, 2021
(Filed With SEC on May 12, 2021)
-
Form of Exchange Agreement
(Filed With SEC on February 2, 2021)
-
Certificate of Designation Series B Preferred Stock
(Filed With SEC on February 2, 2021)
-
Unwind Agreement between Boston Therapeutics, Inc., Cure DM, Inc. and Cure DM Group Holdings, LLC signed August 6, 2019
(Filed With SEC on August 19, 2019)
